Acorda Therapeutics gets grant for sustained release 4-aminopyridine tablets for neurological disorders
Discover Acorda Therapeutics' innovative patent for sustained release 4-aminopyridine tablets, designed for effective once-daily oral administration.
What's Your Reaction?